Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-16. Numbers and descriptions here follow the published literature rather than marketing material.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
==== Judiciary ==== The U.S. federal judiciary consists primarily of the U.S. Supreme Court, the U.S. courts of appeals, and the U.S. district courts. Judges for these courts are appointed under Article III: They are nominated by the president, confirmed by the Senate, and hold office subject to good behavior (generally resulting in life tenure). To limit outside interference, their compensation may not be reduced while they remain in office. Congress has also created Article I courts under its legislative powers; unlike Article III judges, whose tenure and compensation are protected by the Constitution, Article I judges generally serve fixed statutory terms. Federal district courts are the primary trial courts of the federal judiciary and hear civil and criminal cases within their jurisdiction, including cases arising under federal statutes, the Constitution, or international treaties. Decisions of federal district courts may generally be challenged to a federal court of appeals. The U.S. judicial system's 12 regional circuits divide the country into geographic regions for appellate purposes, while the Federal Circuit has nationwide jurisdiction over specified types of cases. The Supreme Court is the highest court in the federal judiciary. It has both original and appellate jurisdiction and exercises judicial review, under which it may hold laws or governmental actions unconstitutional. On average, the Supreme Court receives about 7,000 petitions for writs of certiorari each year but grants review in about 80 cases.
According to a classified (secret) report by the US Army National Ground Intelligence Center in Military Intelligence Digest dated 24 January 1997, agent designated A-232 and its ethyl analogue A-234 developed under the Foliant programme "are as toxic as VX, as resistant to treatment as soman, and more difficult to detect and easier to manufacture than VX". The binary versions of the agents reportedly use acetonitrile and an organic phosphate "that can be disguised as a pesticide precursor."
=== Frabelle Fishing Corporation === Tiu Laurel became the president of the Frabelle Fishing Corporation in 1985 and its director in 2010. The family-owned business, which was established by Tiu Laurel's parents in 1966, is engaged in a variety of business interests in the agricultural and fisheries industry, such as deep-sea fishing, aquaculture, canning, meat and seafood processing, cold-chain network, shipbuilding and repair, and power generation. Frabelle operates in the Asia-Pacific region and supplies domestically in the Philippines and internationally. Concurrently, Tiu Laurel served as President of the Confederation of the Philippine Tuna Industry from 2002 to 2006, director of the Interland Deep Sea Fishing Sector, director of the World Tuna Purse Seine Organization, and chairman of the Processing Sector of Bangus (Milkfish) Council of the Philippines.
Bowman, Mary Margaret Coughlin (1978). "Presidential Emergency Powers Related to International Economic Transactions: Congressional Recognition of Customary Authority". Vanderbilt Journal of Transnational Law. 11 (3): 515–534. Campbell, Tom (2023). "Presidential Authority to Impose Tariffs". Louisiana Law Review. 83 (2): 595–618. Christopher Casey; Jennifer Elsea; Dianne Rennack (2024). The International Emergency Economic Powers Act: Origins, Evolution, and Use (Report). Congressional Research Service. Marks, Lee R.; Grabow, John C. (1982). "President's Foreign Economic Powers After Dames & Moore v. Regan: Legislation by Acquiescence". Cornell Law Review. 68 (1): 68–103. Meezan, David M. (1996). "Forgotten Rights: Takings Claims and the International Emergency Economic Powers Act". Vermont Law Review. 21 (2): 591–632.
=== Immediate-spin cross-matching === Immediate-spin cross-matching (ISCM) is an abbreviated form of cross-matching that is faster, but less sensitive; its primary use is to detect a mismatch between ABO blood types. It is an immediate test that involves combining the patient's serum and donor's red blood cells at room temperature, then centrifuging the sample and observing for agglutination or hemolysis. A lack of agglutination or hemolysis indicates a negative test reaction, or compatible match. ISCM is not appropriate in all circumstances; if the recipient's antibody screen is positive, or if they have had a positive antibody screen in the past, a full crossmatch is performed instead.
Sources: en.wikipedia.org
phosphorylation Aside from cleavage, phosphorylation is perhaps the most important chemical modification of proteins. A phosphate group can be attached to the sidechain hydroxyl group of serine, threonine and tyrosine residues, adding a negative charge at that site and producing an unnatural amino acid. Such reactions are catalyzed by kinases and the reverse reaction is catalyzed by phosphatases. The phosphorylated tyrosines are often used as "handles" by which proteins can bind to one another, whereas phosphorylation of Ser/Thr often induces conformational changes, presumably because of the introduced negative charge. The effects of phosphorylating Ser/Thr can sometimes be simulated by mutating the Ser/Thr residue to glutamate. glycosylation A catch-all name for a set of very common and very heterogeneous chemical modifications. Sugar moieties can be attached to the sidechain hydroxyl groups of Ser/Thr or to the sidechain amide groups of Asn. Such attachments can serve many functions, ranging from increasing solubility to complex recognition. All glycosylation can be blocked with certain inhibitors, such as tunicamycin. deamidation (succinimide formation) In this modification, an asparagine or aspartate side chain attacks the following peptide bond, forming a symmetrical succinimide intermediate. Hydrolysis of the intermediate produces either aspartate or the β-amino acid, iso(Asp). For asparagine, either product results in the loss of the amide group, hence "deamidation".
A 2009 multisite randomized controlled study found no benefit and some adverse effects in autistic children from citalopram, raising doubts about whether SSRIs are effective for treating repetitive behavior in children with autism. Some research suggests citalopram interacts with cannabinoid protein-couplings in the rat brain, and this is put forward as a potential cause of some of the drug's antidepressant effects.
Plasminogen, sold under the brand name Ryplazim, is a biologic medication for the treatment of hypoplasminogenemia (plasminogen deficiency type 1). It is purified from human plasma and is administered intravenously. The most common side effects include abdominal pain, bloating, nausea, bleeding, limb pain, fatigue, constipation, dry mouth, headache, dizziness, joint pain, and back pain. Individuals with hypoplasminogenemia lack a protein called plasminogen, which is responsible for the ability of the body to break down fibrin clots. Plasminogen deficiency leads to an accumulation of fibrin, causing the development of growths (lesions) that can impair normal tissue and organ function and may lead to blindness when these lesions affect the eyes. Plasminogen, human-tvmh was approved for medical use in the United States in June 2021. It is the first therapy for hypoplasminogenemia approved by the U.S. Food and Drug Administration (FDA).
improve awareness and understanding of antimicrobial resistance through effective communication, education and training. strengthen the knowledge and evidence base through surveillance and research. reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures. optimize the use of antimicrobial medicines in human and animal health. develop the economic case for sustainable investment that takes account of the needs of all countries and to increase investment in new medicines, diagnostic tools, vaccines and other interventions. Steps towards progress
Sources: en.wikipedia.org
dbAMP is an online resource that addresses various topics such as annotations of antimicrobial peptides (AMPs) including sequence information, antimicrobial activities, post-translational modifications (PTMs), structural visualization, antimicrobial potency, target species with minimum inhibitory concentration (MIC), physicochemical properties, or AMP–protein interactions. Tools such as PeptideRanker, PeptideLocator, and AntiMPmod allow for the prediction of antimicrobial peptides while others have been developed to predict antifungal and anti-Tuberculosis activities.
Associated bone infections can include septic bursitis, septic tenosynovitis, and osteomyelitis. Septic arthritis and skin and soft tissue infections often present visible and/or systematic symptoms, while osteomyelitis usually presents localized pain.
Cangrelor, sold under the brand name Kengreal among others, is a P2Y12 inhibitor FDA approved as of June 2015 as an antiplatelet drug for intravenous application. Some P2Y12 inhibitors are used clinically as effective inhibitors of adenosine diphosphate-mediated platelet activation and aggregation. It is authorized as a generic medication.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.